company background image
DVAX

Dynavax Technologies NasdaqCM:DVAX Stock Report

Last Price

US$11.63

Market Cap

US$1.5b

7D

-7.3%

1Y

-15.1%

Updated

08 Dec, 2022

Data

Company Financials +
DVAX fundamental analysis
Snowflake Score
Valuation6/6
Future Growth0/6
Past Performance4/6
Financial Health5/6
Dividends0/6

DVAX Stock Overview

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States.

Dynavax Technologies Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Dynavax Technologies
Historical stock prices
Current Share PriceUS$11.63
52 Week HighUS$17.48
52 Week LowUS$7.26
Beta1.33
1 Month Change-6.59%
3 Month Change-0.17%
1 Year Change-15.11%
3 Year Change78.10%
5 Year Change-37.97%
Change since IPO-87.63%

Recent News & Updates

Recent updates

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Sep 12
Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?

Jun 03
Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?

Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest

May 12
Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest

Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt

May 10
Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt

Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly

Jan 28
Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly

Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value

Nov 18
Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value

These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Reasonably Well

Oct 02
These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Reasonably Well

Upgrade: Analysts Just Made A Meaningful Increase To Their Dynavax Technologies Corporation (NASDAQ:DVAX) Forecasts

Aug 10
Upgrade: Analysts Just Made A Meaningful Increase To Their Dynavax Technologies Corporation (NASDAQ:DVAX) Forecasts

Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?

May 30
Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?

Need To Know: Analysts Are Much More Bullish On Dynavax Technologies Corporation (NASDAQ:DVAX) Revenues

May 09
Need To Know: Analysts Are Much More Bullish On Dynavax Technologies Corporation (NASDAQ:DVAX) Revenues

Is There An Opportunity With Dynavax Technologies Corporation's (NASDAQ:DVAX) 43% Undervaluation?

May 02
Is There An Opportunity With Dynavax Technologies Corporation's (NASDAQ:DVAX) 43% Undervaluation?

Dynavax Technologies Corporation (NASDAQ:DVAX) Could Be Less Than A Year Away From Profitability

Apr 11
Dynavax Technologies Corporation (NASDAQ:DVAX) Could Be Less Than A Year Away From Profitability

How Much Of Dynavax Technologies Corporation (NASDAQ:DVAX) Do Institutions Own?

Mar 21
How Much Of Dynavax Technologies Corporation (NASDAQ:DVAX) Do Institutions Own?

Dynavax Technologies (NASDAQ:DVAX) Is Carrying A Fair Bit Of Debt

Feb 28
Dynavax Technologies (NASDAQ:DVAX) Is Carrying A Fair Bit Of Debt

Upgrade: Analysts Just Made A Huge Increase To Their Dynavax Technologies Corporation (NASDAQ:DVAX) Forecasts

Feb 02
Upgrade: Analysts Just Made A Huge Increase To Their Dynavax Technologies Corporation (NASDAQ:DVAX) Forecasts

A Look At Dynavax Technologies' (NASDAQ:DVAX) Share Price Returns

Jan 16
A Look At Dynavax Technologies' (NASDAQ:DVAX) Share Price Returns

How Many Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Do Institutions Own?

Dec 12
How Many Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Do Institutions Own?

Shareholder Returns

DVAXUS BiotechsUS Market
7D-7.3%0.5%-2.8%
1Y-15.1%-8.6%-19.6%

Return vs Industry: DVAX underperformed the US Biotechs industry which returned -11.2% over the past year.

Return vs Market: DVAX exceeded the US Market which returned -21.2% over the past year.

Price Volatility

Is DVAX's price volatile compared to industry and market?
DVAX volatility
DVAX Average Weekly Movement7.6%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: DVAX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: DVAX's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996311Ryan Spencerhttps://www.dynavax.com

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B.

Dynavax Technologies Corporation Fundamentals Summary

How do Dynavax Technologies's earnings and revenue compare to its market cap?
DVAX fundamental statistics
Market CapUS$1.48b
Earnings (TTM)US$320.34m
Revenue (TTM)US$732.06m

4.6x

P/E Ratio

2.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DVAX income statement (TTM)
RevenueUS$732.06m
Cost of RevenueUS$300.95m
Gross ProfitUS$431.11m
Other ExpensesUS$110.77m
EarningsUS$320.34m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)2.51
Gross Margin58.89%
Net Profit Margin43.76%
Debt/Equity Ratio44.2%

How did DVAX perform over the long term?

See historical performance and comparison